Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Amneal Pharmaceuticals Inc
(NQ:
AMRX
)
7.810
-0.050 (-0.64%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 14, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
2,155,350
Open
7.930
Bid (Size)
7.810 (2)
Ask (Size)
7.970 (1)
Prev. Close
7.860
Today's Range
7.665 - 7.930
52wk Range
5.010 - 8.150
Shares Outstanding
1,000
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
AMRX Stock Earnings: Amneal Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024
August 09, 2024
AMRX stock results show that Amneal Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via
InvestorPlace
Amneal Reports Second Quarter 2024 Financial Results
August 09, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Performance
YTD
+30.60%
+30.60%
1 Month
+5.83%
+5.83%
3 Month
+14.01%
+14.01%
6 Month
+39.46%
+39.46%
1 Year
+25.76%
+25.76%
More News
Read More
Amneal Receives U.S. FDA Approval for IPX203 for Treatment of Parkinson’s Disease to Be Launched as CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules
August 07, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Receives U.S. FDA Approval for Potassium Phosphates Injection IV Bags
July 29, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal to Report Second Quarter 2024 Results on August 9, 2024
July 11, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Launches FOCINVEZ™, the First Ready-to-Use Version of Fosaprepitant
July 09, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Amneal for Commercialization of a Proposed Biosimilar to XOLAIR® (Omalizumab)
July 01, 2024
From
Kashiv BioSciences, LLC
Via
Business Wire
Amneal Expands Biosimilars Portfolio to Eight Products with Addition of Omalizumab Biosimilar
July 01, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Amneal Releases 2023 Environmental, Social and Governance Report
June 28, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
3 Stocks to Buy That Are Up 100% Over the Past 52 Weeks
June 25, 2024
Via
InvestorPlace
Amneal Expands Broad Injectables Portfolio to Over 40 Products with the Addition of Six New Therapies
June 05, 2024
From
Amneal Pharmaceuticals, Inc.
Via
Business Wire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.